ArticleBioinformation2025
Effect of multiparametric MRI and ultrasound-guided biopsy for early prostate cancer detection: A prospective cohort study.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is essential to detect clinically significant prostate cancer (csPCa) in an early and precise manner. However, there are challenges given that the usual TRUS-guided biopsy may leave tumors undiagnosed, or only detect indolent disease. In this prospective cohort study of 200 patients, we compared the diagnostic accuracy of multiparametric MRI (mpMRI) with TRUS-guided biopsy. The study found better sensitivity (91% vs 68%) and specificity (76% vs 60%) than TRUS biopsy, and identified 22% more clinically significant cancers than TRUS biopsies. In addition, mpMRI showed better positive predictive value and negative predictive value than TRUS-guided biopsy; this suggests general advantage in diagnostic accuracy and performance for mpMRI. Data shows, there is support for mpMRI having improved efficacy as a method of detecting clinically significant prostate cancer early compared to TRUS-guided biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.